Oxybutynin extended release for the management of overactive bladder: A clinical review

A. M. Arisco, E. K. Brantly, Stephen R Kraus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.

Original languageEnglish (US)
Pages (from-to)151-161
Number of pages11
JournalDrug Design, Development and Therapy
Issue number3
StatePublished - 2009

Fingerprint

Overactive Urinary Bladder
Withholding Treatment
Interpersonal Relations
Self Concept
Workplace
Therapeutics
Quality of Life
Pharmacology
Depression
Drug Therapy
oxybutynin
Pharmaceutical Preparations
Population

Keywords

  • Antimuscarinic
  • Overactive bladder
  • Oxybutynin
  • Urinary urge incontinence

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Oxybutynin extended release for the management of overactive bladder : A clinical review. / Arisco, A. M.; Brantly, E. K.; Kraus, Stephen R.

In: Drug Design, Development and Therapy, No. 3, 2009, p. 151-161.

Research output: Contribution to journalArticle

@article{293e5fb6a023410f981c808774a44da5,
title = "Oxybutynin extended release for the management of overactive bladder: A clinical review",
abstract = "Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.",
keywords = "Antimuscarinic, Overactive bladder, Oxybutynin, Urinary urge incontinence",
author = "Arisco, {A. M.} and Brantly, {E. K.} and Kraus, {Stephen R}",
year = "2009",
language = "English (US)",
pages = "151--161",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Oxybutynin extended release for the management of overactive bladder

T2 - A clinical review

AU - Arisco, A. M.

AU - Brantly, E. K.

AU - Kraus, Stephen R

PY - 2009

Y1 - 2009

N2 - Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.

AB - Overactive bladder (OAB) is a common condition which negatively impacts the quality of life of afflicted patients. This can result in alterations in social interactions at home, in the workplace and in the community, often leading to depression and poor self esteem as well as loss of productivity. Traditional mainstays of treatment include both behavioral therapy and pharmacotherapy. Oxybutynin immediate release (IR) represents the first such medication approved by the FDA specifically for treatment of OAB in 1975. Nevertheless, bothersome side effects in addition to thrice daily dosing often led to treatment cessation which raised the question that patients may actually prefer to live with their OAB symptoms rather than incur side effects or complex dosing schemes. Pharmacological advances ultimately led to development of a long-acting formulation of oxybutynin in the form of oxybutynin extended release (ER) with the hope that this drug would maintain efficacy while decreasing bothersome side effects and improve compliance with the convenience of once daily dosing regimen. This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its use.

KW - Antimuscarinic

KW - Overactive bladder

KW - Oxybutynin

KW - Urinary urge incontinence

UR - http://www.scopus.com/inward/record.url?scp=77953658366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953658366&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77953658366

SP - 151

EP - 161

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

IS - 3

ER -